Bristol Myers Squibb stock falls 3.97 percent on pipeline doubts

Published on 10/05/2026 at 23:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock faces a USD 59.00 Leerink target after a cut from USD 73.00 on October 5, 2026. Second-quarter revenue reached USD 12.97 billion, up 5.7 percent year over year.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb stock (ISIN US1101221083) was trading at USD 58.73 on the NYSE on October 5, 2026, down 3.97 percent during the session. As Yahoo Finance reported on October 5, Leerink Partners cut its rating from Outperform to Market Perform and reduced its price target from USD 73.00 to USD 59.00.

Pipeline doubts reset the target

The downgrade centers on Bristol Myers Squibb's late-stage development portfolio. Leerink analyst David Risinger cited lower conviction in upcoming clinical readouts, including the Phase 3 program for Admilparant and trials for Milvexian, according to Yahoo Finance.

The new USD 59.00 target stands 0.46 percent above the USD 58.73 intraday price. The contrast is important: the target was cut by USD 14.00, or 19.18 percent, while the shares were trading 14.18 percent below the broader consensus target of USD 67.06.

Quarterly growth offers a counterpoint

Bristol Myers Squibb's latest reported quarter supplied stronger operating figures. For the second quarter of 2026, revenue was USD 12.97 billion, up 5.7 percent from the prior-year quarter, while EPS reached USD 2.04 against a USD 1.60 consensus, according to MarketBeat.

The same report said fiscal 2026 EPS guidance stood at USD 6.75-7.00. That outlook gives the pipeline debate a measurable earnings baseline, but the downgrade shows that investors are placing greater weight on the timing and commercial performance of future medicines.

Consensus stays above the market

MarketBeat counted 25 analysts in its consensus, including two Strong Buy, twelve Buy, ten Hold and one Sell rating. The resulting Moderate Buy label carries an average target of USD 67.06, with the target sitting 14.18 percent above the October 5 intraday price.

Bristol Myers Squibb is scheduled to report third-quarter 2026 results on October 29, 2026, according to the company's investor calendar. The next earnings date is therefore the clearest near-term checkpoint for testing whether second-quarter growth can offset the pipeline concerns.

Stock trades near the session low

Bristol Myers Squibb stock was last at USD 58.73 on the NYSE on October 5, 2026 at 3:37 p.m. EDT, within a session range of USD 58.33 to USD 60.15. Its 52-week range was USD 42.52 to USD 68.64, and its market capitalization was USD 120.0 billion.